Madrigal Pharmaceuticals Future Growth
Future criteria checks 5/6
Madrigal Pharmaceuticals is forecast to grow earnings and revenue by 64.4% and 55.5% per annum respectively. EPS is expected to grow by 63.5% per annum. Return on equity is forecast to be -138.5% in 3 years.
Key information
64.4%
Earnings growth rate
63.5%
EPS growth rate
Biotechs earnings growth | 25.9% |
Revenue growth rate | 55.5% |
Future return on equity | -138.5% |
Analyst coverage | Good |
Last updated | 23 Jul 2024 |
Recent future growth updates
Recent updates
Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 970 | 98 | -89 | -194 | 13 |
12/31/2025 | 364 | -405 | -361 | -481 | 15 |
12/31/2024 | 75 | -584 | -492 | -560 | 16 |
3/31/2024 | N/A | -444 | -391 | -389 | N/A |
12/31/2023 | N/A | -374 | -326 | -324 | N/A |
9/30/2023 | N/A | -347 | -303 | -303 | N/A |
6/30/2023 | N/A | -330 | -277 | -277 | N/A |
3/31/2023 | N/A | -315 | -259 | -259 | N/A |
12/31/2022 | N/A | -295 | -225 | -225 | N/A |
9/30/2022 | N/A | -274 | -215 | -214 | N/A |
6/30/2022 | N/A | -256 | -201 | -201 | N/A |
3/31/2022 | N/A | -247 | -191 | -190 | N/A |
12/31/2021 | N/A | -242 | -184 | -184 | N/A |
9/30/2021 | N/A | -236 | -191 | -191 | N/A |
6/30/2021 | N/A | -231 | -193 | -193 | N/A |
3/31/2021 | N/A | -219 | -171 | -170 | N/A |
12/31/2020 | N/A | -202 | -158 | -158 | N/A |
9/30/2020 | N/A | -171 | -115 | -115 | N/A |
6/30/2020 | N/A | -134 | -79 | -78 | N/A |
3/31/2020 | N/A | -105 | -66 | -66 | N/A |
12/31/2019 | N/A | -84 | -42 | -42 | N/A |
9/30/2019 | N/A | -68 | -36 | -36 | N/A |
6/30/2019 | N/A | -55 | -30 | -30 | N/A |
3/31/2019 | N/A | -42 | -23 | -23 | N/A |
12/31/2018 | N/A | -33 | -26 | -26 | N/A |
9/30/2018 | N/A | -30 | -25 | -25 | N/A |
6/30/2018 | N/A | -30 | -25 | -25 | N/A |
3/31/2018 | N/A | -32 | -27 | -27 | N/A |
12/31/2017 | N/A | -31 | N/A | -22 | N/A |
9/30/2017 | N/A | -30 | N/A | -22 | N/A |
6/30/2017 | N/A | -36 | N/A | -26 | N/A |
3/31/2017 | N/A | -31 | N/A | -21 | N/A |
12/31/2016 | N/A | -26 | N/A | -18 | N/A |
9/30/2016 | N/A | -21 | N/A | -13 | N/A |
6/30/2016 | N/A | -8 | N/A | -5 | N/A |
3/31/2016 | N/A | -7 | N/A | -3 | N/A |
12/31/2015 | N/A | -7 | N/A | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDGL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: MDGL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MDGL is expected to become profitable in the next 3 years.
Revenue vs Market: MDGL's revenue (55.5% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: MDGL's revenue (55.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDGL is forecast to be unprofitable in 3 years.